Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. possesses a comprehensive portfolio of innovative gene editing tools, including programmable nucleases and CRISPR-associated transposases, which contribute to its robust pipeline targeting serious genetic disorders. The company's approach has demonstrated significant efficacy, achieving durable FVIII levels of 80% in non-human primates over a 19-month period, indicating strong therapeutic potential for conditions such as Hemophilia A. Furthermore, Metagenomi's dual strategy of advancing its wholly-owned pipeline while pursuing technology out-licensing for ex vivo cell therapy enhances its growth prospects and market adaptability.

Bears say

Metagenomi reported a substantial net loss of $19.9 million for the second quarter of 2025, translating to a loss of $0.54 per share. Despite trading significantly below its cash reserves, which could suggest potential for recovery, several risks loom over the company, including possible delays in clinical advancements and the potential failure to produce positive clinical data from key programs, particularly for Hemophilia A and TTR. Additionally, the risk of long-term dilution could further exacerbate the negative outlook on the stock.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.